Sean Michael O'Connell

US Patent:

20220401477, Dec 22, 2022

Filed:

May 17, 2022

Appl. No.:

17/746307

Inventors:

- Houston TX, US
Lilit Garibyan - Newton MA, US
Beverly W. Lubit - Kinnelon NJ, US
Sean O'Connell - Budd Lake NJ, US

Assignee:

VERDURE BIOTECH, INC. - Houston TX

International Classification:

A61K 35/17
A61P 37/04

Abstract:

The invention of the present disclosure provides a method for treating a viral infection in a recipient subject suffering from or at risk of a viral infection including administering to the recipient subject a pharmaceutical composition comprising a therapeutic amount of superactivated cytokine killer T cells (SCKTCs) and a pharmaceutically acceptable carrier, and mobilizing an immune response of the recipient subject to the viral pathogen. When tested in vitro, the SCKTCs are characterized by a predominant production of T1 dominant cytokines including IFN-γ; an IFN-γ:IL-4 ratio of at least 500:1; and at least 50% killing of target A549 cells at an effector:target ratio of 20:1. The present disclosure further provides a method of preparing a pharmaceutical composition comprising an enriched population of superactivated cytokine killer T cells (SCKTCs) wherein pulsing steps with monocyte-derived dendritic cells (DCs) loaded with alpha-GalCer achieve at least an 80% pure population of SCKTCs without positive or negative cell separation methods.

US Patent:

20220249651, Aug 11, 2022

Filed:

Jan 31, 2022

Appl. No.:

17/589484

Inventors:

- Coral Springs FL, US
Lilit Garibyan - Newton MA, US
Helen Hao - Piscataway NJ, US
Sean O'Connell - Budd Lake NJ, US

Assignee:

AEGLE BIOTECH - Coral Springs FL

International Classification:

A61K 39/145
A61P 31/16
C07K 14/005
C12N 15/86
C12N 7/00

Abstract:

The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (T) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene under the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.